v3.25.3
Segment Reporting (Tables)
 9 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
Schedule of Segment Loss, Including Significant Segment Expenses
Segment loss, including significant segment expenses, for the three and nine months ended September 30, 2025 and 2024 is as follows (in thousands):
Three Months Ended September 30,
Nine Months Ended September 30,
2025202420252024
Product revenues, net$142,342 $93,425 $342,580 $259,265 
Less:
Cost of product revenues (excluding amortization of intangible assets)29,365 21,170 78,718 59,591 
ARIKAYCE external R&D expenses9,214 16,370 32,338 45,192 
Brensocatib external R&D expenses19,355 17,288 73,576 74,612 
TPIP external R&D expenses28,754 16,635 58,556 45,190 
Other external R&D expenses36,579 26,919 93,107 55,111 
R&D compensation and benefit-related expenses63,817 50,778 173,764 136,146 
SG&A compensation and benefit-related expenses62,287 47,578 168,443 115,250 
Other segment items(a)
150,930 94,721 398,275 261,889 
Depreciation2,458 1,459 6,825 4,483 
Amortization of intangible assets1,538 1,263 4,064 3,789 
Change in fair value of deferred and contingent consideration liabilities104,653 14,682 181,953 106,482 
Investment income(18,289)(16,982)(45,420)(36,050)
Interest expense20,382 21,054 63,196 63,363 
Provision for income taxes1,320 1,014 3,475 2,441 
Segment net loss$(370,021)$(220,524)$(948,290)$(678,224)

(a) Other segment items include stock-based compensation, professional fees, and facility-related expenses.